Navigation Links
Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Date:9/9/2009

tters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
2. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
3. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
4. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
5. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
6. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
7. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
8. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
9. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
10. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
11. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... R.I. , Sept. 2, 2015  Neurotech ... been enrolled in the multicenter Phase 2 clinical ... the long-term treatment of recurrent subfoveal choroidal neovascularization ... NT-503 is a unique vascular endothelial growth factor ... ECT implant. "This landmark proof-of-concept study ...
(Date:9/2/2015)... ZIONA, Israel , September 2, 2015 ... BVXV) today announced the intent of the National Institute of ... Institutes of Health (NIH) within the Department of Health and ... to be held in the United States ... use of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as ...
(Date:9/2/2015)... ... September 02, 2015 , ... The TS5-Q is ... commercial video content, to analysis of athletic performance. Producing high-resolution slow-motion video ... too quickly to process with the naked eye. , Slow motion sequences ...
(Date:9/1/2015)... , Sept. 1, 2015  ContraVir Pharmaceuticals, Inc. ... the development and commercialization of targeted antiviral therapies, announced ... Renshaw 17 th Annual Global Investment Conference sponsored ... September 8-10, 2015 at The St. Regis Hotel in ... James Sapirstein , Chief Executive Officer, will ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... Designation Process and Saves Lives, HARRISBURG, Pa., Aug. ... Web portal that will enable individuals to,sign up as ... driver,s,license or photo ID card is up for renewal ... Web portal, http://www.donatelife-pa.org, will link visitors to ...
... - Despite outcome, CEO Mark McDade to resign ... 20 PDL BioPharma, Inc.,(PDL) (Nasdaq: PDLI ... the company,s chief executive officer (CEO), Mark McDade,found ... breach of,fiduciary duty by McDade to corroborate the ...
... Fisher,Scientific Inc. (NYSE: TMO ) announced today ... and chief executive,officer, are adopting stock- trading programs ... the future sale of company stock. Mr.,Dekkers, who ... August,15-17, 2007, has adopted a plan for the ...
Cached Biology Technology:Web Portal Makes Organ Donation Easy 2PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 2PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 3PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 4Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs 2
(Date:8/24/2015)...  Based on its recent analysis of the biometric products ... Biometrics Company of the Year Award. DERMALOG is the leading ... Africa . It has particularly gained prominence ... one of the largest biometric mass applications in the world, ... Bank of Nigeria with its biometric ...
(Date:8/20/2015)... SANTA CLARA, Calif. , Aug. 20, 2015 ... based company focused on improving the user experience ... voice and vision technologies, today announced that its ... and voice biometric authentication software to be ... Alliance tested TrulySecure for compliance with the FIDO ...
(Date:8/19/2015)... 19, 2015  VOXX International Corporation (Nasdaq: ... into a Definitive Agreement to purchase the assets, ... market leader EyeLock through an acquiring entity.  Upon ... controlling interest in the acquiring entity. The closing ... due diligence.  Expanding on its existing supply chain ...
Breaking Biology News(10 mins):Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... that send water surging through swamps and marshes near rivers ... gas emissions from those affected wetlands, according to recent research ... of water through wetlands result in lower average emissions of ... the emissions from wetlands that receive a steady flow of ...
... California White Mountain Research Station, U.S. Forest Service ... Climate Research in Western Mountains will host a ... Fairgrounds in Bishop. The conference is entitled "Climate, ... bring together distinguished researchers from a variety of ...
... treat breast cancer or prevent its recurrence should think ... report. Genistein, a soy isoflavone that mimics the ... effectiveness of aromatase inhibitors, which are designed to reduce ... in some types of breast cancer. The new ...
Cached Biology News:Flooding might help lower gas emission from wetlands 2Flooding might help lower gas emission from wetlands 3The dietary supplement genistein can undermine breast cancer treatment 2The dietary supplement genistein can undermine breast cancer treatment 3
... GelSpin Kit utilizes a silica based spin filter ... electrophoresis, the desired DNA band is cut from ... spin filter unit. The gel slice is melted ... the DNA is bound to the silica spin ...
... to HDAC4 - ChIP Grade HDAC4 ... mammalian histone deacetylases, which consists of 1084 ... highly similar to the deacetylase domain of ... between the nucleus and cytoplasm in a ...
... Vector is a derivative of the pAcHLT-A Vector ... fluorescent protein (BFP), followed by a 6xHis tag ... expressed as BFP-6xHis fusion proteins when cloned into ... Stu I, Sac I, Not I, Pst I, ...
Mouse monoclonal antibody to ALAS2 - aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)...
Biology Products: